

TREATMENT OR PROPHYLAXIS  
OF ISCHEMIC HEART DISEASE

INS B1

BACKGROUND OF THE INVENTION

insc

5 This invention relates to a pharmaceutical composition for reducing an infarct region resulting from the ischemic necrosis of cells, the pharmaceutical composition containing a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor.

10 This invention also relates to a method for reducing an infarct region resulting from the ischemic necrosis of cells, comprising administering said substance or pharmaceutical composition to a patient with ischemic disease.

15 In recent years, ischemic heart disease has posed a major problem in an aging population. Of cardiac diseases which are diseases of circulatory organs, myocardial infarction ascribed to cardiovascular disorder, in particular, is a serious, potentially fatal disease which  
20 either obstructs the coronary artery or substantially decreases the blood flow resulting in ischemic necrosis of myocytes and deteriorating cardiac function. The direct cause of myocardial infarction is a decrease or interruption of the blood flow to the myocardium due to  
25 coronary arteriosclerosis or thrombus formation in the coronary artery. The disease can result in either acute or chronic cardiac failure. Methods adopted for treatment of ischemic heart disease include the dilatation of the

obstructed coronary artery by use of an intravascularly  
inserted balloon, maintenance of blood flow by  
intravascular insertion of a stent, and dissolution and  
removal of a thrombus formed in the blood vessel with the  
5 use of a thrombolytic agent. With any of such treatments,  
it is known that as blood flow is restored in the coronary  
artery, Ca overload or free radicals occur, increasing the  
region of cellular necrosis. Prevention of the occurrence  
of such ischemia-reperfusion injury is difficult, and no  
10 effective method of treatment has been established.

#### SUMMARY OF THE INVENTION

The present invention provides a pharmaceutical  
composition for reducing an infarct region resulting  
from the ischemic necrosis of cells, the pharmaceutical  
15 composition containing a substance, as an active ingredient,  
which can increase intracellular cGMP production by acting  
on a natriuretic peptide receptor.

The present invention also provides a method for  
reducing an infarct region resulting from the ischemic  
20 necrosis of cells, comprising administering said substance  
or pharmaceutical composition to a patient with ischemic  
disease.

More specifically, the invention provides a  
pharmaceutical composition and a method for suppressing  
25 ischemia-reperfusion injury in the treatment of ischemic  
disease.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a view illustrating acute myocardial

infarction models of Example, showing the state of ischemia-reperfusion, and the mode of administration in 1) a physiological saline treatment group (B group), and 2) an hANP treatment group (A group);

5           FIG. 2 is a view showing a region at risk for myocardial infarction in each group of the acute myocardial infarction models in FIG. 1; and

          FIG. 3 is a view showing the ratio (%) of a region of myocardial infarction to the region at risk for  
10           myocardial infarction in each group.

#### DETAILED DESCRIPTION OF THE INVENTION

          hANP, a natriuretic peptide, is used as an agent of symptomatic therapy for alleviating symptoms of cardiac failure, because it has a diuretic action, and exhibits a  
15           blood pressure lowering effect by promoting production of cGMP, which is considered to be a second messenger of relaxation in vascular smooth muscle cells, to induce relaxation of blood vessels (e.g., coronary artery).

          The inventors of the present invention further  
20           studied the properties of natriuretic peptides, and found for the first time that these peptides can reduce an infarct region occurring in a model of acute myocardial infarction involving ischemia reperfusion. This finding led them to accomplish this invention.

25           That is, the present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of ischemic heart disease, such as myocardial infarction, the pharmaceutical composition containing a

substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region. In the present invention, "to reduce an infarct region" means to suppress enlargement of an infarct region.

The present invention also relates to a method for treatment or prophylaxis of ischemic disease, comprising administering a substance to a patient with ischemic disease, which substance can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region. The method of the present invention is especially effective for suppressing ischemia-reperfusion injury.

Whether a certain substance can become the active ingredient of a pharmaceutical composition for use in the treatment or prophylaxis of ischemic disease, the pharmaceutical composition related to the present invention, can be investigated by using a known method, for example, the methods described in Minamitake, Y., et al., Biochem. Biophys. Res. Commun., 172, 971-978 (1990); Furuya, M., et al., Biochem. Biophys. Res. Commun., 170, 201-208 (1990); Furuya, M., et al., Biochem. Biophys. Res. Commun., 177, 927-931 (1991); Hidaka, H. et al., Folia Pharmacologica Japonica, 101, 309-325 (1993).

Preferred as the substance as an active ingredient according to the present invention are natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic

peptide (BNP) and C-type natriuretic peptide (CNP). Of them, ANP and BNP are preferred, and ANP is the most preferred.

INS A1> As ANP, there can be used human ANP (human atrial  
5 natriuretic peptide; hANP, Kangawa et al., Biochem. Biophys.  
Res. Commun., Vol. 118, p. 131, 1984) (Seq. ID No. 1) or  
rat ANP (Kangawa et al., Biochem. Biophys. Res. Commun.,  
Vol. 121, p. 585, 1984) (Seq. ID No. 2), each ANP  
comprising 28 amino acids. The peptide as the active  
10 ingredient in the present invention may be a peptide having  
a ring structure of ANP (formation of a disulfide bond  
based on Cys), and a C-terminal portion succeeding the ring  
structure. An example of such a peptide is a peptide  
having amino acid residues at the 7-position to the 28-  
15 position of ANP (Seq. ID No. 3). Another example is frog  
ANP (Seq. ID No. 5). Of them, human ANP (hANP) is  
particularly preferred.

To: This paragraph should be INS A1>  
An example of BNP is human BNP comprising 32 amino  
acids and involving the formation of a disulfide bond, like  
20 the above-described ANP (Sudoh et al., Biochem. Biophys.  
Res. Commun., Vol. 159, p. 1420, 1989) (Seq. ID No. 4).  
Various BNP's of the origin other than human, such as pig  
BNP (Seq. ID No. 6) and rat BNP (Seq. ID No. 7), are also  
known, and can be used similarly. A further example is  
25 chicken BNP (Seq. ID No. 8).

Examples of CNP are pig CNP comprising 22 amino  
acids and involving the formation of a disulfide bond, like  
the above-described ANP and BNP (Sudoh et al., Biochem.

Biophys. Res. Commun., Vol. 168, p. 863, 1990) (Seq. ID No.

9; human and rat also have the same amino acid sequence),

chicken CNP (Arimura et al., Biochem. Biophys. Res. Commun.,

Vol. 174, p. 142, 1991) (Seq. ID No. 10), and frog CNP

5 (Yoshihara et al., Biochem. Biophys. Res. Commun., Vol. 173,  
p. 591, 1990) (Seq. ID No. 11).

Furthermore, any person skilled in the art can apply  
modification, such as deletion, substitution, addition or  
insertion, and/or chemical modification to amino acid  
10 residues in the amino acid sequence of a known natriuretic  
peptide (e.g., the aforementioned human ANP; hANP), as  
desired, by a known method. One skilled in the art can  
confirm that the resulting compound is a compound which has  
the activity of acting on a receptor of ANP to increase  
15 cGMP production. Derivatives having this activity,  
therefore, are included in the substance as an active  
ingredient which is administered to a patient in accordance  
with the method of the present invention. Moreover, the  
substances involved in the present invention are not  
20 restricted to the above peptides, as long as they are  
substances capable of acting on a natriuretic peptide  
receptor to increase intracellular cGMP production. These  
substances may be non-peptide compounds.

The substance as an active ingredient according to  
25 the present invention may be of a free type, or its  
pharmaceutically acceptable salt. The salt with an  
inorganic acid includes, for example, salts with  
hydrochloric acid, sulfuric acid, and phosphoric acid.

The salt with an organic acid may, for example, be acid addition salts with formic acid, acetic acid, butyric acid, succinic acid, and citric acid. The salt may be in the form of a metal salt with sodium, potassium, lithium or calcium, or a salt with an organic base.

The substance as an active ingredient is preferably mixed with known pharmaceutically acceptable carriers, vehicles, or diluents, and administered by an administration method used generally for drugs, for example, an oral administration method, or a parenteral administration method, such as intravenous administration, intracoronary administration, intramuscular administration, or subcutaneous administration. The pharmaceutical composition of the present invention can be produced, for example, by mixing, as desired, the active ingredient, pharmaceutically acceptable carriers, flavors, vehicles, and stabilizers. To produce solid preparations for oral administration, such as tablets, capsules, granules, and fine granules, the following additives can be used: (1) vehicles such as lactose, starch, and microcrystalline cellulose, (2) binders such as hydroxypropylcellulose, and polyvinylpyrrolidone, (3) disintegrants such as starch and crosscarmellose sodium, (4) plasticizers such as macrogol and triethyl citrate, (5) lubricants such as magnesium stearate and talc, (6) coating materials such as hydroxypropyl methylcellulose, and Eudragit, and (7) taste correctives such as sucrose and mannitol, odor correctives, and colorants.

To produce injections, ophthalmic solutions, or transnasal preparations, the following additives can be added: (1) tonicity agents such as sodium chloride, D-mannitol, and D-sorbitol, (2) pH regulators such as hydrochloric acid and citric acid, (3) buffering agents such as sodium citrate, sodium acetate, and boric acid, and (4) soothing agents such as procaine hydrochloride; as well as stabilizers, and surface active agents. In consideration of the stability, etc. of the active ingredient, it can be selected whether the active ingredient should be formed into a preparation to be used after dissolution or suspension when required, or into a liquid preparation.

To produce preparations for external use, such as ointments and cataplasms, the following materials can be added: (1) bases such as liquid petrolatum, petrolatum, and hydrophilic ointments, (2) emulsifying agents such as polysorbate 80, and tragacanth, (3) preservatives such as sodium benzoate, and propyl p-hydroxybenzoate, and (4) soothing agents such as procaine hydrochloride, stabilizers, and surface active agents.

When the substance as an active ingredient is a natriuretic peptide, this peptide orally administered is degraded in the digestive tract, and thus this mode of administration is generally not effective. However, the peptide can be orally administered in the form of a preparation minimally degraded in the digestive tract, for example, microcapsules comprising the peptide, as the



active ingredient, enclosed in a liposome. A mode of administration by absorption through the mucosa other than the digestive tract, such as the rectum or a sublingual area, is also possible. In this case, a dosage form, such as a suppository or a sublingual tablet, can be used for administration.

*Inc2* The dose of the pharmaceutical composition of the present invention differs according to the age, the body weight, the severity of symptoms of, and the route of administration in, a patient with myocardial infarction or a patient potentially developing myocardial infarction. When the substance as an active ingredient is a natriuretic peptide, the pharmaceutical composition can be administered at a dose of 0.01  $\mu\text{g/kg/min}$  to 0.2  $\mu\text{g/kg/min}$ , and is preferably administered in a dose of 0.025  $\mu\text{g/kg/min}$  to 0.1  $\mu\text{g/kg/min}$ , by the continuous intravenous route.

#### Example

The following example shows that hANP, a natriuretic peptide, reduces the region of myocardial infarction occurring in models of acute myocardial infarction involving ischemia reperfusion.

#### Method

Thoracotomy was performed in 12 adult beagles weighing 14 to 23 kg under anesthesia with pentobarbital sodium, and hANP (0.1  $\mu\text{g/kg/min}$ ) was continuously administered for 10 minutes into the left anterior descending branch (LAD) of the coronary artery. Then, the LAD was completely obstructed into an ischemic state until

the LAD was reperfused 90 minutes later. hANP (0.1  
µg/kg/min) was continuously administered into the LAD over  
the course of 1 hour since 10 minutes before initiation of  
reperfusion. After 6 hours of reperfusion, a region at  
5 risk of developing infarction was evaluated by Evans blue  
staining, and the region of infarction was evaluated by TTC  
staining (Group A: 5 dogs). After 80 minutes of ischemia,  
the amount of endocardial collateral blood flow was  
measured by the microsphere method. A group receiving  
10 physiological saline, instead of hANP, into the LAD was  
provided as a control group (Group B: 7 dogs).

A protocol for the experiments is shown in FIG. 1.  
In the drawing, CPP denotes coronary perfusion pressure.  
The protocol shows that blood flowed in the LAD before  
15 start of the test, then the blood flow was interrupted  
for 90 minutes, then blood flow was restored again, and  
the test was completed at 360 minutes. The amount of  
endocardial collateral blood flow during ischemia, the mean  
blood pressure, and the heart rate were also measured to  
20 investigate whether or not these parameters took part in  
the effect of the hANP according to the present invention.

### Results

(1) FIG. 2 shows the size of the region at risk of  
myocardial infarction in the left ventricle of each test  
25 group. There was no significant difference between the  
test groups in the size of the region at risk of myocardial  
infarction.

(2) In the models of acute myocardial infarction

involving ischemia reperfusion, the hANP administration reduced the region of myocardial infarction. As shown in FIG. 3, the region of myocardial infarction in the control group (Group B) was  $41 \pm 3\%$  of the region at risk of

5 myocardial infarction, while the region of myocardial infarction significantly decreased to  $21 \pm 5\%$  in the hANP group (Group A).

(3) No difference was confirmed between the groups in terms of the amount of endocardial collateral blood flow 10 during ischemia. Moreover, changes in the heart rate and the mean blood pressure in each group were measured 5 and 10 minutes after start of the test, 90 minutes after initiation of ischemia, and 360 minutes after start of reperfusion. The mean blood pressure and the heart rate 15 were confirmed to remain unchanged following administration of hANP.

The above findings demonstrate that the administration of a natriuretic peptide suppresses ischemia-reperfusion injury in the treatment of ischemic 20 disease. Thus, the effect of reducing the region of myocardial infarction is confirmed to be ascribed to the natriuretic peptide's action of reducing the region of myocardial infarction.